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Abstract
In HIV-infected women, co-infections that target the placenta, fetal membranes, genital tract, and 
breast tissue, as well as systemic maternal and infant infections, have been shown to increase the 
risk for mother-to-child transmission of HIV (MTCT). Active co-infection stimulates the release 
of cytokines and inflammatory agents that enhance HIV replication locally or systemically and 
increase tissue permeability, which weakens natural defenses to MTCT. Many maternal or infant 
co-infections can affect MTCT of HIV, and particular ones, such as genital tract infection with 
herpes simplex virus, or systemic infections such as hepatitis B, can have substantial 
epidemiologic impact on MTCT. Screening and treatment for co-infections that can make infants 
susceptible to MTCT in utero, peripartum, or postpartum can help reduce the incidence of HIV 
infection among infants and improve the health of mothers and infants worldwide.
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INTRODUCTION
Despite the success of antenatal HIV screening and prevention of mother-to-child 
transmission of HIV (PMTCT) programs, in 2009, an estimated 370,000 children became 
infected during the perinatal or breastfeeding period [1]. Highly effective interventions for 
PMTCT, such as antiretroviral agents during pregnancy and labor [2-9], caesarean section 
delivery [10-13], postexposure prophylaxis to the infant [14-18], and avoidance of 
breastfeeding [19, 20], can reduce risk for mother-to-child transmission of HIV (MTCT) to 
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<2% [21-23]. Unfortunately, these interventions are not uniformly administered, particularly 
in resource-limited countries with the greatest need [24].
Effective PMTCT interventions address the main risk factors for MTCT, which are maternal 
HIV load and infant exposure to infected fluids [25, 26]. High maternal HIV load is the 
strongest risk factor for MTCT, and reduction of HIV load with antiretroviral interventions 
significantly reduces risk [27-34]. Infant exposure to infected fluids during labor and 
delivery is associated with duration of ruptured membranes [35], type of delivery [10, 11], 
and presence of other active sexually transmitted infections (STIs) in the vaginal canal [25, 
36, 37]. Postnatal exposure to HIV-contaminated milk is correlated with duration of 
breastfeeding, which is associated with MTCT [20]. Without PMTCT intervention, the 
overall risk for HIV transmission to the infant is 25%-40%, with an estimated 10%-25% of 
infections occurring during pregnancy, 35%-40% during labor and delivery, and 35%-40% 
during breastfeeding [26, 38].
In the absence of antiretroviral treatment, natural defense mechanisms can protect against 
MTCT. The human placenta is an efficient barrier to the exchange of maternal and fetal 
circulations, despite HIV tropism for placental cells and frequent infection of the placenta 
[39]. Postpartum, the blood-milk barrier keeps the HIV load in breast milk generally 100 
times lower than the HIV load in plasma [40], possibly because of the many antimicrobial 
and immunomodulatory factors in breast milk [41, 42], including cell-free HIV inhibitors 
that likely inactivate many potentially infectious virions [43-45]. Disruption of natural 
barriers to infection occurs during chorioamnionitis, labor and delivery, or mastitis, and 
these barrier breaches can increase risk for MTCT. Co-infections can trigger the release of 
inflammatory agents that increase tissue permeability and cytokines that stimulate HIV 
replication [46, 47]. Several co-infections in the HIV-infected mother or exposed infant have 
been shown to increase MTCT risk, and addressing these co-infections may reduce MTCT 
and improve overall maternal and child health (Table 1) [48].
MATERNAL REPRODUCTIVE TRACT INFECTIONS
Infections of the Placenta and Fetal Membranes
In HIV-infected, pregnant women who are not taking antiretrovirals, the placenta is a 
reservoir for HIV replication [49]; however, it can also provide an efficient barrier to HIV 
transmission for more than 90% of exposed infants [39]. Evolution of the placenta’s 
structure and function during gestation generates a barrier between maternal and fetal 
circulations through which HIV must cross by endocytosis or by an injured villous surface, 
such as occurs in chorioamnionitis. The placenta also confers protection by producing 
soluble factors and receptors, such as cytokines, chemokines, and MHC class I molecules. 
Co-infections of the placenta may affect its anti-HIV properties by altering local expression 
of cytokines, chemokines, and their co-receptors, as evidenced by increased expression of 
the CCR5 HIV co-receptor on placental macrophages infected with malaria in a Plasmodium 
falciparum dominated region [50], or by stimulating HIV replication, as evidenced in vitro 
with an antigen of P. falciparum [51].
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Chorioamnionitis is inflammation of the membranes surrounding the fetus that is caused 
primarily by infection ascending from the lower genital tract. It can be caused by several 
different microorganisms, such as bacterial vaginosis-associated bacteria, Neisseria 
gonorrhea, Chlamydia trachomatis, Trichomonas vaginalis, or Group B Streptococcus [52]. 
Chorioamnionitis may disrupt the placental barrier allowing HIV-infected maternal 
lymphocytes to enter the amniotic fluid. It has been associated with increased intrauterine 
risk for MTCT [53-57], but it has not necessarily been found to be an independent risk factor 
[29, 58]. Chorioamnionitis is also associated with preterm labor and premature rupture of the 
membranes [59]. These conditions have been associated with increased MTCT [60-63], but 
the causality of the association is unclear because HIV infection predisposes women to 
preterm delivery [64]. In a Kenyan study of 250 mother-infant pairs, histologic 
chorioamnionitis was found to be an independent risk factor for peripartum MTCT (adjusted 
odds ratio [AOR], 3.9; 95% confidence interval [CI], 1.2-12.5) after researchers assessed the 
effect of prolonged rupture of membranes and controlled for low infant birth weight and 
maternal plasma and genital tract HIV load [53]. Similarly, in a study conducted at seven 
sites in the United States (n=175), acute histologic chorioamnionitis was found significantly 
more often in placental tissue from HIV-infected mothers who transmitted the virus to their 
infants than from mothers who did not transmit the virus to their infants (37.5% vs 11.3%, 
p=0.008), and it remained a predictor after adjustment for HIV load and prolonged rupture 
of membranes [54]. In this study, histologic chorioamnionitis was significantly correlated 
with clinical chorioamnionitis, but clinical chorioamnionitis was not a predictor of MTCT. 
This study also assessed whether HIV load influenced the association between histologic 
chorioamnionitis and transmission and found no interaction. A study in former Zaire (now 
DRC) found chorioamnionitis to be associated with MTCT in both univariate and 
multivariate analyses (AOR, 2.5; 95% CI, 1.2-5.2), with a significant interaction between 
maternal immune status and the effect of chorioamnionitis; only among 
nonimmunocompromised women (as indicated by neither a low CD4+ T lymphocyte count 
nor an elevated CD8+ T lymphocyte count) was chorioamnionitis associated with 
significantly increased risk of HIV transmission (relative risk, 4.2; 95% CI, 1.3-13.7) [55]. 
An interaction between maternal immune status and the effect of chorioamnionitis on 
MTCT was also observed in a Ugandan study in which, in the absence of immune 
suppression, the AOR for MTCT was 2.87 (95% CI, 1.04-7.90) for women with 
chorioamnionitis when they were compared with women who did not have chorioamnionitis 
[56]. These data suggest that inflammation of the placental membranes may have a greater 
effect on risk for transmission among women who might otherwise be at low risk for 
perinatal transmission. Using the assumption that the association between chorioamnionitis 
and HIV transmission among nonimmunocompromised women is causal, the authors in the 
Ugandan study estimated that up to 34% of HIV transmissions could be prevented with 
treatment of placental inflammation in non-immunocompromised women. However, a 
randomized controlled trial that evaluated two courses of antibiotic treatment at 20-24 weeks 
gestation (metronidazole 250 mg and erythromycin 250 mg, three times per day, orally for 7 
days) and during labor (metronidazole 250 mg and ampicillin 500 mg every 4 hours) among 
HIV-infected and uninfected pregnant women in Africa failed to show an effect on 
histologic chorioamnionitis or risk for MTCT [65, 66]. As a result, the study was terminated 
early by the data safety and monitoring board overseeing the research. This trial, as well as 
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an observational cohort study in Africa that systematically screened and treated common 
STIs, documented no difference in MTCT by the presence of histologic chorioamnionitis 
[66, 67].
Lower Genital Tract Infections
Genital tract infections increase intrapartum risk for MTCT by increasing infant exposure to 
HIV in genital secretions from the mother during labor and delivery. Common vaginal 
infections such as bacterial vaginosis (BV) and vulvovaginal candidiasis, STIs such as 
trichomoniasis and herpes simplex virus type 2 (HSV-2), and cervicitis are associated with 
increased HIV shedding in the genital tract that declines upon treatment for these infections 
[26, 68-72].
HSV-2 is the leading cause of genital ulcers. With a seroprevalence of 60%-90% among 
HIV-infected populations, it likely has a significant effect on HIV infection [73]. HSV-2 
ulcers contain high levels of HIV RNA, possibly from the homing of activated T cells [74, 
75], and also provide a breach in the mucosa that increases infant exposure to HIV virions or 
infected cells beneath the epithelium. Consequently, genital ulcers are an important risk 
factor for MTCT [25,36,37,76]. Even among clinically asymptomatic, serologically positive 
women, HSV-2 shedding remains common and is associated with increased HIV shedding 
in the genital tract of co-infected women [77, 78]. Two studies, one in the United States and 
one in Kenya, found that clinical HSV-2 was associated with increased MTCT but 
asymptomatic HSV-2 was not [36, 37]. More recently, two nested case-control studies from 
Thailand and Zimbabwe found that serologic HSV-2 was associated with increased risk for 
MTCT, independent of maternal HIV load [76, 79]. In the Thai study, genital HSV-2 
shedding was independently associated with a threefold increase in intrapartum HIV 
transmission [76]. In the Zimbabwe study, an estimated 28.4% of intrapartum HIV 
transmissions were potentially attributable to serologic HSV-2 infection [79]. Asymptomatic 
HSV-2 infection may affect MTCT through more generalized effects on the mother’s HIV 
load because of immune activation or direct interactions between the viruses [80]. Plasma 
HIV load increases upon subclinical HSV-2 reactivation and declines upon successful viral 
suppression with acyclovir treatment [81-83]. Clinical trials have shown that HSV-2 
suppressive therapy significantly reduces plasma and cervical HIV load [46, 83-88]. 
However, results from clinical trials of acyclovir on sexual transmission of HIV have shown 
no reduction in acquisition or transmission [86,89,90].
Acyclovir is actively transported to the amniotic fluid and breast milk [91], and both 
acyclovir and valacyclovir, which is rapidly absorbed and converted to acyclovir, have good 
safety profiles in pregnant women and have not been associated with congenital 
malformations or infant toxicity [92-94]. The maternal and infant safety profile for 
maternally administered valacyclovir suppressive therapy was not altered in the context of 
antiretroviral prophylaxis for PMTCT in a randomized trial [95]. In another report from this 
trial, which was conducted among pregnant and postpartum Kenyan women co-infected 
with HSV-2 and HIV, valacyclovir significantly reduced HIV load in plasma by 0.5 log10 
copies/mL during pregnancy and after 6 weeks postpartum, compared with the placebo, and 
reduced the levels of HIV load in breast milk at 6 and 14 weeks postpartum [96]. 
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Theoretically, suppression of HIV load in plasma and breast milk should translate to reduced 
MTCT. The Kenyan trial found no difference in HIV transmission at 12 months, but the 
study was not designed to answer this question. Larger clinical trials are warranted because 
suppressive therapy for HSV-2 could be easily administered within the existing PMTCT 
infrastructure and could provide maternal benefits of reduced frequency and severity of 
HSV-2 reactivations, which may slow HIV disease progression, and reduce the risk for HIV 
transmission.
Syphilis, caused by infection with the bacterium Treponema pallidum, is a less common 
cause of genital ulcer disease, and its role in MTCT is unclear [79, 97-100]. One large 
prospective cohort study conducted in Malawi reported that syphilis was associated with a 
2.7-fold increase in both intrauterine (HIV-positive at birth) and intrauterine/postpartum 
(HIV-positive at 6 or 12 weeks postpartum) MTCT after adjustment for maternal HIV load 
and other confounders [97]. A study in Ukraine in which researchers were unable to adjust 
for maternal HIV load reported that serologically confirmed syphilis was associated with a 
fivefold increase in MTCT [98]. However, studies conducted in Zimbabwe and Texas found 
no association between active syphilis and perinatal HIV transmission [79, 100]. These 
findings are consistent with the Rakai trial of presumptive treatment of STIs, which reported 
reductions in maternal rates of bacterial STIs but not in perinatal HIV transmission [101].
Human papilloma virus (HPV) infection is the most common STI, and its prevalence, 
incidence, and persistence are highly correlated with HIV infection and immune status [102, 
103]. Some HPV types may cause genital warts, and two studies have reported a significant, 
unadjusted association between genital warts and increased risk for MTCT among co-
infected women [54, 104]. This finding may be secondary to genital warts acting as a proxy 
for advanced HIV disease and higher maternal HIV load.
In women who have BV, the healthy vaginal flora is replaced with high levels of anaerobic 
microorganisms and byproducts that can damage vaginal epithelium and degrade cervical 
mucus. Evidence suggests that BV increases women’s risk for STIs, including gonorrhea, 
chlamydial infection, trichomoniasis, HPV, herpes simplex virus, and HIV [105-109]. 
Among HIV-infected women, BV is associated with increased shedding of HIV in the 
genital tract. In a recent prospective study in Kenya, HIV-infected women diagnosed with 
BV at 32 weeks gestation had a threefold higher risk for in utero HIV transmission than 
women with normal vaginal flora [110]. However, a multi-site randomized controlled trial 
of metronidazole versus placebo found no difference in MTCT rates, despite a 16% 
reduction in BV [66]. Further studies are needed to answer the question of whether 
restoration of normal vaginal flora can reduce MTCT.
Treatment of concurrent genital infections can reduce genital HIV shedding [72], but 
whether this translates to reduced MTCT is unknown. Besides the aforementioned 
treatments for specific infections, randomized trials of virucidal vaginal washes, such as 
benzalkonium chloride or diluted chlorhexidine, on MTCT have failed to consistently 
demonstrate an effect [111-114].
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Breast milk contains both antimicrobial and immunomodulatory factors that protect infants 
against various infectious diseases and support the development of the infant’s immune 
system. Because breast milk contains cell-free HIV inhibitors and because of the milk-blood 
barrier [42], the concentration of HIV is typically 10-100 times lower in breast milk than in 
plasma [34]. However, infection or inflammation of breast tissue can increase the HIV load 
in breast milk, which is a strong predictor of postnatal transmission [34].
An estimated 10%-33% of women experience mastitis, typically during the early 
breastfeeding period or during the mixed feeding and weaning stages. Clinical mastitis may 
be characterized by cracked nipples and sores, suppuration, pain, swelling, and erythema. 
Cracked nipples frequently bleed during infant feeding, thereby increasing the exposure to 
plasma and cell-associated virus, and several studies have reported associations between 
cracked or bleeding nipples and increased postnatal transmission of HIV [115, 116]. 
Subclinical mastitis is characterized by an elevated milk leukocyte count or elevated sodium 
or sodium/potassium ratio. Like clinical mastitis, it can alter the cellular tight junctions that 
regulate breast epithelial permeability. Both clinical and subclinical mastitis are associated 
with increased HIV load in breast milk [117-122] and its correlate, postnatal HIV 
transmission [25, 116, 117, 119, 121], and researchers have estimated that up to 50% of 
postnatal transmissions may be attributable to the more common subclinical mastitis [123].
Most mastitis is sterile inflammation with isolation of only normal skin flora, but up to 
40%-50% of subclinical and clinical mastitis cases may be attributable to Staphylococcus 
aureus [124, 125]. A study among 75 HIV-infected, postpartum women with subclinical 
mastitis in Malawi evaluated the effect of oral amoxicillin/clavulanic acid on breast milk 
leukocyte count and HIV load. One week after treatment, there was a >50% reduction in the 
proportion of mothers with elevated breast milk leukocyte counts; after 4-12 weeks, study 
results showed a significant reduction in breast milk HIV load compared with baseline data 
[126]. However, the HIV load remained higher among women with past clinical mastitis 
than among those without mastitis at baseline. These findings suggest that the effect of 
inflammation on the alveolar ducts persists for several weeks after treatment.
Interestingly, mastitis has been associated with increased breast milk concentrations of α-
defensins, a group of anti-HIV peptides released by the innate immune system, and 
researchers have suggested that mastitis may provide a protective effect when HIV load is 
low in plasma [127]. An analysis of plasma and breast milk samples collected as part of a 
study in Zimbabwe found that mastitis was associated with postnatal transmission of HIV 
only when HIV load was high in maternal plasma (>3.7 log10 copies/mL) [121]. For women 
with HIV loads <3.7 log10 copies/mL, the point estimate for the odds of postnatal 
transmission was in the direction of a protective effect (0.26; 95% CI, 0.04-1.94). These data 
suggest that, when HIV loads are low in maternal plasma, the increased immune factors in 
breast milk associated with mastitis may outweigh the effect of any increase in HIV 
replication.
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In many parts of the world, including sub-Saharan Africa, it is common for mothers to 
premasticate food for their infants during the weaning period [128]. In 2009, there was a 
case series report of three pediatric HIV infections among infants who were HIV-negative at 
birth, not breast fed, and had no known causes of infection besides exposure to food 
premasticated by a HIV-infected caregiver [129]. For two of the infants, it was a HIV-
infected mother who premasticated the food; for the other infant of an HIV-negative mother, 
it was an HIV-infected great aunt. In two of the cases, there was evidence of bleeding gums. 
The exposure to blood in premasticated food along with the compromised oral mucosa of an 
infant may facilitate transmission via premasticated food. A case-control investigation in 
2010 at 6 U.S. HIV clinics found no significant difference between 11 infants with late-
diagnosed HIV-infection and 35 HIV-exposed, uninfected infants in the proportion that were 
fed food premasticated by an HIV-infected caregiver (27% vs 20%, respectively) [130]. This 
report also presented the findings from a cross-sectional investigation of premastication 
prevalence, which was 31% among 154 primary caregivers of children aged ≥6 months. 
Premastication appears to be a rather common practice of caregivers, but it is 
contraindicated for HIV-infected caregivers [131].
MATERNAL SYSTEMIC CO-INFECTIONS
As mentioned, maternal HIV load is highly correlated with risk for HIV transmission to the 
infant [29, 30, 132-134], and concurrent, systemic maternal infections can inadvertently 
stimulate HIV replication and increase HIV load. Any infection that raises maternal plasma 
HIV load, and its correlates, HIV load in the genital tract and in breast milk, could affect the 
risk for HIV transmission.
Hepatitis B
Up to 90% of HIV-infected persons worldwide have serologic evidence of hepatitis B virus 
(HBV) infection, and 10% have chronic HBV [135, 136]. Co-infection with HIV accelerates 
the rate of disease progression of HBV infection and is associated with an increased carriage 
rate for the hepatitis B e antigen, chronic HBV infection, and high HBV DNA levels, all of 
which are associated with increased risk for MTCT of HBV [136-141]. Among women with 
very high HBV DNA levels during pregnancy (>109 copies/mL), HBV transmission to the 
infant is substantial (as high as 32%) despite immunoprophylaxis with vaccine and 
immunoglobin [142]. Although HIV/HBV co-infection may be related to increased HBV 
transmission to the infant, HBV infection, as measured by the presence of hepatitis B 
surface antigen, does not seem to be independently associated with increased MTCT of HIV 
[143, 144]. However, women co-infected with HIV/HBV are significantly more 
immunosuppressed than HIV-monoinfected women, which is an independent risk factor for 
MTCT [145].
Hepatitis C
Although hepatitis C virus (HCV) infection is less common than HBV, rates of co-infection 
among HIV-infected persons are about 30% worldwide, and the prevalence of HCV 
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infection is particularly high among HIV-positive injection drug using women [145, 146]. 
HIV-infected persons exposed to HCV are less likely to clear the virus spontaneously, and 
upon infection, co-infected persons have increased HCV RNA levels in plasma and progress 
to cirrhosis faster than HCV-monoinfected persons [147-149]. Increased maternal HCV 
RNA levels are associated with perinatal transmission of HCV [150-154], and HIV-co-
infected mothers are at increased risk for perinatal transmission of HCV [150, 151, 155, 
156]. With respect to the role of HCV infection on MTCT of HIV, HIV disease progression, 
and death, the data are conflicting. HCV seropositivity is associated with severe 
immunosuppression among HIV-infected persons (p<.001) [145], and several studies have 
documented increased risk for MTCT of HIV among co-infected women [155-159]. The 
likely mechanism for increased MTCT associated with HCV seropositivity is increased 
maternal HIV load.
GB Virus C
GB virus C (GBV-C) is a flavivirus closely related to HCV that was discovered in 1995 
[160]. Although no clinical disease has been associated with GBV-C, it can be transmitted 
vertically and has been associated with reduced MTCT of HIV [161, 162].
Cytomegalovirus
Cytomegalovirus (CMV) seropositivity in HIV-infected adults is almost universal, and the 
two viruses can infect the same cell types, with the viral products of each virus capable of 
activating the other virus in vitro. Researchers have hypothesized that the two infections are 
interrelated, with each virus predisposing a person to a higher risk of contracting the other 
virus. The prevalence of congenital CMV infection among infants born to HIV-infected 
women is relatively high, with rates ranging from 2% to 7% [163-168]; rates in the general 
newborn population are 0.7% [169]. A simple bivariate analysis of data from eight studies 
(n=6,265) suggests that congenital CMV infection occurs significantly more often among 
HIV-infected infants (9%) than those who are not infected (2%) [165], but this comparison 
was heavily weighted by the largest study of 4,797 infants in the French Perinatal Cohort 
Study. Findings from that study also suggest a role of maternal immunosuppression in 
increased CMV transmission based on a lower risk for congenital CMV infection among 
HIV-infected mothers after highly active antiretroviral therapy became available [166]. A 
recent study in Thailand of 97 HIV-infected infants and 196 HIV-exposed uninfected infants 
matched for maternal HIV load reported that congenital CMV infections were more 
common in HIV-infected (14%) than HIV-uninfected (3%) infants [170]. This study also 
examined the timing of CMV infection relative to HIV infection and found that in utero 
CMV infection correlated with both in utero and intrapartum HIV infection, whereas 
intrapartum CMV infection correlated with intrapartum, but not in utero, HIV infection, 
suggesting that fetal CMV infection may predispose infants to in utero HIV infection. In 
vitro studies have also described the ability of CMV to facilitate HIV infection [171-173]. 
Infants with CMV and HIV infection may be more prone to rapid progression of HIV 
disease [167].
King et al. Page 8














Another almost universal HIV co-infection is Epstein-Barr virus (EBV). In a multi-site U.S. 
study of 279 HIV-infected, pregnant women who were also EBV seropositive, EBV 
shedding was marginally associated with MTCT of HIV [61]. However, this association did 
not reach statistical significance in a multivariate analysis that adjusted for maternal immune 
status and other confounders.
HHV-6
HIV-infected mothers also seem to transmit human herpes virus 6 (HHV-6) to infants more 
frequently than HIV-uninfected mothers [174]. However, a study of perinatally HIV-
infected infants from Thailand found the rate of HHV-6 infection was lower in HIV-infected 
children, but that HHV-6 co-infection correlated with faster progression of HIV disease 
[175].
HHV-8
Cross-sectional studies have demonstrated a significant association between the 
seroprevalences of HIV and HHV-8, also known as Kaposi’s Sarcoma-associated 
herpesvirus [176-179]. In Sub-Saharan Africa, where HHV-8 is highly prevalent, infection 
is commonly acquired in childhood through exposure to infected saliva from other children 
or caregivers, with the seroprevalence generally increasing with age [180-182]. Vertical 
transmission of HHV-8 during birth or through breast milk is rare [177, 180-185]; HHV-8 is 
rarely detected in breast milk [186]. Two large studies, a prospective study in Zambia [184] 
and a cross-sectional study in South Africa [187], found that maternal HHV-8 status was not 
an independent risk factor associated with HHV-8 transmission to children, suggesting that 
other household or non-familial contacts contribute to horizontal transmission. These studies 
also reported that maternal HIV status does not affect infant HHV-8 status. Infant HIV 
status, however, was an important predictor, and both studies reported a significant 
increased risk for HHV-8 among HIV-infected children [184, 187]. A small study of 15 co-
infected, pregnant women in Italy found that HHV-8 load significantly increased late in 
pregnancy and was associated with a significant increase in HIV-1 shedding in the genital 
tract, suggesting that HHV-8 co-infection may increase MTCT of HIV [188]. However, 
results from a study in Zambia failed to show an association between HHV-8 infection and 
transmission of HIV to the infant [177].
Tuberculosis
Tuberculosis (TB) is a leading cause of disease and death worldwide and is of particular 
concern among those infected with HIV, who are 20-30 times more likely to develop TB 
[189]. For women, the greatest burden of TB occurs during the reproductive years (ages 
15-49 years) [190]. Active TB infection increases HIV load and is associated with 
immunosuppression, which may explain the association between TB and MTCT [191-195]. 
To date, few studies have investigated whether TB increases the risk for MTCT 
independently of HIV load. A small study of 42 HIV-infected, pregnant women with active 
TB in South Africa reported a 19% rate of in utero transmission, which was higher than the 
5%-10% rate reported in resource-limited countries at that time [195]. A recent study in 
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India found that maternal TB was associated with a 2.5-fold increase in the odds for MTCT 
after adjusting for maternal and infant factors [196].
Malaria
Populations with a high prevalence of both HIV and parasitic infections overlap 
geographically and socio-economically. In addition, the level of immune compromise 
associated with HIV increases a person’s susceptibility to parasitic diseases. Concurrent 
infection causes chronic immune activation, which increases the risk for reactivation of both 
infections and higher HIV load.
In the most severely affected countries in Sub-Saharan Africa, more than 10% of adults are 
HIV-infected and more than 90% are exposed to malaria. Pregnant women are at increased 
risk for malaria which is associated with intrauterine growth retardation, preterm delivery, 
low birth weight, still birth, early neonatal death, and maternal anemia [197, 198], especially 
among primigravidae women, among whom malaria tends to be more severe. HIV infection 
further increases the risk for malaria parasitemia and clinical malaria, and among pregnant 
women, the risk of placental malaria and adverse birth outcomes [199-202]. Furthermore, 
new evidence suggests that malaria parasites may be more likely to develop wild-type 
mutations after exposure to sulfadoxine-pyrimethamine as intermittent preventive treatment 
during pregnancy among HIV-infected women [203]. Malaria also has been associated with 
a temporary increase in HIV replication and plasma HIV load [204, 205], and associations 
with blood parasitemia and MTCT of HIV may be secondary to an increase in maternal HIV 
load. Placental malaria has been associated with increased placental and plasma HIV load 
[206]. Several studies have examined the association between placental malaria and MTCT 
of HIV independently of HIV load or CD4+ T lymphocyte count, with inconsistent results 
[207-212]. The effect may be limited to cases with high parasitemia (>10,000 parasites/ml), 
as suggested by a study in Western Kenya, where the risk for MTCT increased when 
parasitemia was high but decreased when it was low (<10,000), compared with malaria-
negative controls [202]. Other studies have shown associations between placental malaria 
and placental characteristics that may increase susceptibility to in utero HIV infection, such 
as placental inflammation [213], increased CC-chemokine production [214, 215], a shift in 
cytokine production from Th2 to Th1-type responses [216], and increased expression of the 
CCR5 HIV co-receptor on placental macrophages [50]. Inconsistencies in study results may 
be due, in part, to differences in the epidemiology of malaria in different settings, which 
could affect maternal immunity, or to different methods of detecting placental parasitemia. 
Although it remains unknown whether malaria increases MTCT, malaria during pregnancy 
is associated with obstetrical problems and adverse birth outcomes and warrants extensive 
screening and intervention programs in endemic areas.
Other Parasitic Co-Infections
Toxoplasmosis is a parasitic disease caused by the protozoon Toxoplasma gondii, and it is 
estimated that 25% to 30% of people world wide are infected [217]. Congenital toxoplasma 
infection results from primary maternal infection or reactivation of a past infection during 
pregnancy, with the risk of congenital toxoplasma transmission ranging from 10% during 
the first trimester, when the placental barrier is most efficient, to 60-70% in the third 
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trimester [218]. Conversely, the severity of fetal damage is greatest when infection occurs 
earlier in gestation, which often leads to severe abnormalities or abortion [219]. In HIV-
infected women, the risk of toxoplasmosis, primarily from reactivation of a past infection, 
increases substantially when the CD4+ T lymphocyte count falls below 100 cells/μl. In the 
pre-HAART era, there were case reports of transmission of both toxoplasmosis and HIV to 
infants of co-infected mothers, with many of these infants having rapid HIV disease 
progression [220, 221]. A recent retrospective study of HIV-infected pregnant women and 
their infants in Brazil evaluated predictors for MTCT of HIV, which occurred among 3.7% 
(15/401) of infants. Maternal neurotoxoplasmosis during gestation was associated with a 7 
times higher risk for infant HIV infection, and congenital toxoplasmosis, which occurred in 
6 infants, was associated with 24 times higher risk of infant HIV infection [222].
The protozoan parasite Trypanosoma cruzi, which is endemic to Latin America, causes 
Chagas disease and can be transmitted transplacentally to the fetus. Human placental 
histocultures co-infected with T. cruzi and HIV have shown lower levels of chemokines that 
downmodulate T. cruzi replication (IL-6, IL-8, IP-10, and MCP-1) [223]. Another study 
suggests that T. cruzi inhibits HIV replication at the placental level [224]. However, 
simultaneous congenital transmission of T. cruzi and HIV has been reported [225].
Helminth infections are very prevalent in areas of Asia and Africa [226-229]; they affect 
immune homeostasis [230], which may influence risk for HIV acquisition and progression. 
One study found that women with HIV and helminth infections had a higher risk for MTCT 
of HIV [231]. Two randomized clinical trials have evaluated treatment of helminthic 
infections as a strategy to reduce the progression of HIV disease and found improvements in 
immune responses and CD4+ T lymphocyte counts in persons infected with some helminths 
[232, 233]. Periodic deworming is now recommended in Sub-Saharan Africa as a 
component of comprehensive HIV care for women and children.
INFANT CO-INFECTIONS
Although some infants become infected with HIV in utero, the majority are infected 
perinatally or postnatally. During labor and delivery, infants whose mothers have HIV are 
exposed to infected blood and vaginal secretions that may be inadvertently ingested. 
Prematurity of the skin, mucous membranes, and gastrointestinal tract is the likely 
mechanism for increased risk of HIV infection to premature infants. In newborns, the 
gastrointestinal tract is immature: it has a thin mucosa; lower levels of gastric acidity, 
enzyme activity, and mucus production; and no secretory IgA. These factors increase 
gastrointestinal permeability and make it possible for HIV to traverse the epithelium to the 
lamina propria, where HIV likely infects lymphocytes or is taken up by macrophages [234]. 
Inflammation of the gastrointestinal tract due to infection could weaken barrier defenses and 
facilitate passage of HIV. Some infants may develop oral candidiasis upon colonization 
from exposure to Candida during vaginal delivery. Candidiasis results in inflammation of 
the infant’s oral mucosa and gastrointestinal tract and an influx of activated CD4+ T 
lymphocytes and macrophages; it has also been associated with increased risk for postnatal 
HIV transmission [116].
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Diarrhea is associated with increased intestinal permeability [235], and any infection that 
causes diarrhea has the potential to increase MTCT to exposed infants. Although studies on 
the effects of diarrheal diseases on MTCT are lacking, increased intestinal permeability due 
to contamination of other liquids and foods given to the infant is a proposed biological 
mechanism for the increased risk for postnatal HIV transmission during the first few months 
of life among infants in resource-limited countries who are fed a mix of breast milk and 
other foods compared with infants who are exclusively breastfed [20, 236-238]. Mixed 
feeding poses the same risks for contamination and diarrhea as artificial feeding, but also 
increases intestinal permeability and risk for HIV infection because of continued exposure to 
HIV-infected breast milk.
Co-infections in HIV-infected infants are thought to in part explain the higher risk for death 
by 2 years of age among untreated, HIV-infected children in Sub-Saharan Africa 
(45%-59%) compared to those in Europe and the United States (10%-20%) [239-245]. A 
major cause of stillbirth and neonatal death is untreated maternal syphilis [246]. HIV-
infected women have a higher prevalence of untreated or inadequately treated syphilis 
during pregnancy, which places their newborns at higher risk for congenital syphilis and its 
outcomes, including blindness, deafness, progressive intellectual deterioration, and death 
[100]. In Sub-Saharan Africa, up to 80% of children may acquire CMV during their first 
year of life, regardless of HIV status [247], and MTCT appears to be more frequent among 
infants with congenital CMV infection [167]. HIV and CMV co-infection in infants is 
associated with higher peak CMV viral loads, prolonged detection of CMV in plasma, rapid 
progression of HIV disease, and a greater than twofold increase in risk for death [167, 247, 
248]. Other perinatal viral infections, such as HHV-6, have also been associated with faster 
progression of HIV disease [175].
STRATEGIES FOR PREVENTION AND TREATMENT
Antiretroviral treatment for HIV-infected women during pregnancy, delivery, and 
breastfeeding decreases the risk for MTCT by reducing the HIV load in plasma and breast 
milk, and it improves maternal health by reconstituting CD4+ T lymphocytes and lowering 
her risk for opportunistic infections. Administration of antiretrovirals is the most important 
intervention to decrease MTCT, and these medications should be made available to pregnant 
women in all settings.
Existing PMTCT programs could also incorporate available, inexpensive, and safe strategies 
for the prevention and treatment of co-infections during pregnancy and breastfeeding to 
further reduce MTCT of HIV. The World Health Organization (WHO) currently 
recommends prevention, screening, and treatment for certain infections at antenatal 
consultations [249]. In areas with endemic malaria, WHO recommends that pregnant women 
sleep under insecticide-treated mosquito bed nets and receive 2-3 treatment courses of 
sulfadoxine-pyrimethamine. Screening and treatment for syphilis are recommended at the 
first antenatal visit and ideally repeated at 36 weeks or delivery in areas of high risk. For 
other curable genital tract infections, WHO suggests using syndromic-based algorithms for 
diagnosis and treatment [250]. However, syndromic management has poor sensitivity and 
specificity for many of these infections, which can lead to overtreatment or under treatment 
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in many cases [251, 252]. Several trials are evaluating the use of azithromycin-based 
combination therapies for intermittent use during pregnancy. Azithromycin has shown high 
cure rates (>96.5%) for syphilis, N gonorrhoeae, and C trachomatis, as well as efficacy in 
reducing risk for T vaginalis [253-256]. A meta-analysis of antibiotic therapy for treatment 
of BV in pregnancy showed high efficacy (odds ratio, 0.17: 95% CI, 0.15-0.20; 10 trials, 
4,357 women) and, when administered before 20 weeks, significantly reduced the risk for 
preterm birth [257]. Postpartum, WHO recommends prophylaxis against bacterial and 
protozoan opportunistic infections with cotrimoxazole for HIV-infected mothers and for 
HIV-infected or exposed infants from age 6 weeks throughout breastfeeding and longer for 
infants that are HIV-infected [258].
Given the limitation of syndromic management of certain co-infections, presumptive, 
intermittent treatment of prevalent co-infections for all women may be the preferable 
approach to improving pregnancy outcomes and reducing MTCT of HIV in resource-limited 
countries [259]. Alternatively, novel rapid diagnostic tests are becoming increasingly 
available, and frequent screening throughout the antenatal period and targeted treatment may 
be a better option in some settings. Testing of HIV-infected women for HBV infection 
during pregnancy should be part of routine antenatal care in all settings. This practice can 
guide decisions on selection of appropriate antiretroviral regimens and ensure timely 
administration of HBV vaccine and immunoglobulin to exposed infants [141]. Finally, 
ensuring that women are immunized against important pathogens, such as tetanus, influenza, 
or pertussis, before or during pregnancy can help prevent infections that are associated with 
concurrent immune activation and transient increases in HIV load during pregnancy. 
Immunization of the mother can also protect infants from these pathogens. Expanding HBV 
and HPV vaccine programs to cover young women before pregnancy has the potential to 
offer far-reaching health benefits at the population level.
CONCLUSION
Screening and treatment for co-infections that predispose infants to in utero, peripartum, or 
postpartum HIV infection can help to further reduce the incidence of HIV among infants 
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Table 1
Maternal and Infant Co-Infections that have an Impact on MTCT of HIV
Co-Infection Mechanisms of Affecting MTCT of HIV Intervention Strategies
Chorioamnionitis
Potenital to increase MTCT in utero via 
placental
inflammation or intrapartum via association 
with
preterm labor and premature rupture of 
membranes
Treatment with antibiotics during pregnancy has not
shown value in preventing MTCT of HIV [65, 66]
Lower genital tract infections
(HSV, syphilis, BV, 
trichomoniasis,
etc.)
Potential to increase MTCT in utero and
intrapartum by increased peripheral blood 
HIV
load and increased genital tract HIV shedding 
and
local mucosal inflammation
Treatment of HSV with valacyclovir in pregnant and
postpartum women reduced HIV RNA in plasma and
breast milk [95] but did not reduce MTCT; further 
studies
are needed
Trials of vaginal cleansing have not shown benefit in
reducing MTCT [111-114]
Mastitis Increased MTCT during breastfeeding fromincreased viral load in breast milk
Counseling on proper breastfeeding technique. 
Exclusive
breastfeeding was associated with reduced MTCT of 
HIV,
compared with mixed feeding [20, 236-238]
Antibiotic treatment of mastitis may reduce breast
inflammation [126], however effects on MTCT are
unknown
Gingivitis/Periodontal Disease
Bleeding gums or increased HIV shedding in 
oral
secretions associated with periodontal
inflammation when food is premasticated for
infants by an HIV-infected caregiver




(HBV, HCV, CMV, others)
Increased MTCT due to increased prevalence 
of
co-infections among more 
immunosuppressed
women and increased maternal HIV load
associated with co-infections
Prenatal maternal screening for HBV. If positive, 
infants
should receive hepatitis B vaccine and immune 
globulin
soon after birth [141]




Associated with maternal immune 
suppression and
higher HIV load.
Appropriate maternal treatment with antiretrovirals and
regimens against TB may result in improvement in
immune status and decreases in VL
Malaria
Possibly increased MTCT in utero and 
intrapartum
due to increase in maternal viral load, 
preterm
delivery and low birth weight
Appropriate malaria preventive measures during





Associated with maternal immune 
suppression and
with increased HIV load
Periodic deworming in endemic areas may be 
associated
with improvement in immune status and decreases in 
HIV
load
Screening for toxoplasmosis during pregnancy;
appropriate prophylaxis or treatment, as necessary 
[260]
Infant Oral Candidiasis
Increased MTCT during breastfeeding due to
breaches in oral mucosa and influx of 
activated
CD4+ T lymphocytes and macrophages as 
well as
HIV into the GI tract
Treatment of oral candidiasis will decrease oral 
mucosal
inflammation
Infant Diarrhea Increased MTCT during breastfeeding due toincreased intestinal permeability
Promotion of breastfeeding in resource-limited settings
decreases infant diarrheal disease
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